Seattle Genetics (SGEN) Gets a Hold Rating from Cowen & Co.
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Seattle Genetics (SGEN), with a price target of $80.00. The company’s shares closed last Monday at $101.80, close to its 52-week high of $101.95.
According to TipRanks.com, Peaker is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.8% and a 38.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $90.80.
See today’s analyst top recommended stocks >>
Based on Seattle Genetics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $79.24 million. In comparison, last year the company had a GAAP net loss of $67.45 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
Read More on SGEN: